DGCI Approves Covaxin and 2 Others For Use In 6-12 Year-Olds

Bhubaneswar: The DCGI (Drugs Controller General of India) has given permission for restricted emergency use authorization to Bharat Biotech’s Covaxin for children between the age of 6-12 years.

It is noteworthy that, DCGI has also granted emergency use authorization to ZycovD (Zydus Cadila vaccine) for children above the age of 12 years for a two-dose regimen.

DCGI (Drugs Controller General of India) has granted emergency use authorization to Corbevax for children between the age of 5-12 years said sources.

The DGCI has asked vaccine manufacturer to submit safety data including the data on adverse event with due analysis every 15 days for the first two months and monthly thereafter upto 5 months, said the source familiar with the development.

This development comes after the Subject Expert Committee (SEC) discussed recommendations for the restricted emergency use of Covaxin in children aged between 2-12 years.

However, the SEC, after a meeting on Thursday, had recommended restricted emergency use of Biological E’s Covid-19 vaccine, Corbevax, in children aged 5-12 years.